CareDx (CDNA) Earnings Date & Reports

Key Takeaways

• Total revenue climbed 52% year over year to approximately $132 million, well ahead of the roughly $114 million consensus estimate.
• Testing services revenue surged 61% to $100 million, with testing volume up 17% to about 58,000 tests.
• Non-GAAP (adjusted) earnings per share reached $0.37, compared with a $0.23 consensus estimate and $0.10 in the prior-year quarter.
• GAAP net income was $111 million, boosted by a $113 million gain from the June 30 sale of the Lab Products business to Eurobio Scientific.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose to $25 million from $5 million a year earlier.
• Management raised full-year 2026 revenue guidance to $490 million–$500 million and adjusted EBITDA guidance to $66 million–$78 million.
• For more context, review CDNA's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are approaching stocks like CDNA.

Earnings Context and Why It Matters

CareDx is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. Its second quarter 2026 report carries outsized weight because it reflects a strategic transformation: the company completed the sale of its Lab Products business and closed its acquisition of Naveris, sharpening its focus on high-margin molecular testing. Investors were also watching whether demand for transplant surveillance testing and improving reimbursement dynamics would continue to drive growth. The results confirmed strong commercial momentum across testing services and patient and digital solutions, while the raised guidance signaled management's confidence in a sustained, profitable trajectory.

Reported Results

For the quarter ended June 30, 2026, CareDx reported total revenue of approximately $132 million, up 52% from $87 million a year earlier and above the consensus estimate of roughly $114 million. Testing services revenue increased 61% to $100 million, supported by testing volume of about 58,000 (up 17%), while patient and digital solutions revenue grew 50% to $19 million and lab product revenue rose 8% to $13 million. Average revenue per test was approximately $1,720, including $16 million recognized for tests performed in prior periods.

GAAP net income was $111 million, compared with a net loss of $9 million a year earlier, reflecting a $113 million gain on the Lab Products divestiture that closed June 30. GAAP diluted earnings per share were $2.07. On a non-GAAP basis, which excludes that gain, net income was $20 million and diluted earnings per share were $0.37, versus $0.10 a year ago. Adjusted EBITDA reached $25 million, up from $5 million, aided by strong testing services growth, improved gross profit, and cost discipline. The company ended the quarter with $374 million in cash and no debt, generating $31 million in cash flow from operations.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, supporting a more data-driven approach to identifying setups. Explore the AI Screener to apply these tools to your own watchlist.

Market Reaction and Investor Sentiment

CareDx shares advanced sharply following the report, with the stock rising more than 30% as investors rewarded the top- and bottom-line beats and the raised full-year outlook. The reaction reflected relief that testing demand and reimbursement trends remained favorable, and that the Lab Products divestiture positioned the company as a more focused, higher-margin diagnostics business. Analyst responses were generally constructive, though some remained cautious about the sustainability of prior-period revenue recognition and the ongoing influence of Medicare coverage policy on long-term testing economics.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will watch whether CareDx can sustain its testing services momentum now that the Lab Products segment is no longer included in results. Management's revised 2026 revenue guidance of $490 million to $500 million, and adjusted EBITDA guidance of $66 million to $78 million, imply continued double-digit growth and meaningful margin expansion.

Reimbursement policy remains the most important variable. The company has noted that CMS (the Centers for Medicare & Medicaid Services) finalized Medicare coverage for its AlloSure and AlloMap tests, which supports patient access. However, any future changes to coverage criteria or test frequency could affect volumes and pricing.

Product pipeline progress also matters. CareDx continues to advance AlloHeme toward CLIA (Clinical Laboratory Improvement Amendments) readiness, with an early commercial launch anticipated for 2027. The integration of the acquired Naveris business and its NavDx test will be another area to monitor, as management works to expand beyond solid organ transplant into specialty oncology and cell therapy. Finally, investors should track gross margins, operating expense discipline, and cash collections as signals of whether the company can convert revenue growth into durable profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations